PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Webcasts|June 10, 2020
Comprehensive Analysis into Disintegration Mechanisms: How Reliable Are Textbook Recommendations?
Author(s)JRS Pharma
When formulating a tablet, the solubility of the tablet matrix is often used as the sole criteria for disintegrant selection. Most formulators tend to select swelling-type disintegrants for insoluble matrices and wicking-type disintegrants for soluble matrices. This webcast will present an in-depth analysis of the effects of disintegration mechanisms, pH of test media, matrix plasticity, tablet hydrophobicity, and storage effects on the disintegration behavior. Live: Wednesday, Jun. 10, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Jun. 10, 2021 Register free
Register free:
Event Overview:
When formulating a tablet, the solubility of the tablet matrix is often used as the sole criteria for disintegrant selection. Most formulators tend to select swelling-type disintegrants for insoluble matrices and wicking-type disintegrants for soluble matrices.
This webcast will present an in-depth analysis of the effects of disintegration mechanisms, pH of test media, matrix plasticity, tablet hydrophobicity, and storage effects on the disintegration behavior. In addition, the interaction of disintegrants in the tablet surface with environmental humidity is taken into consideration as an additional element for rational excipient selection.
Key Learning Objectives:
- History of disintegrants and common mechanisms of disintegration
- Performance of superdisintegrants in various tablet matrices and different media
- Influence of high humidity environments on tablet surfaces containing different superdisintegrants
Speaker: Emily Sabath, Scientist Research & Development, JRS PHARMA
Time and date: Wednesday, Jun. 10, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Jun. 10, 2021.
Sponsor: JRS Pharma
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.